Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of reduced dose of Dabigatran, Rivaroxaban and Apixaban in patients with atrial fibrillation for stroke prevention

Next Previous
Search
Trial Profile

Efficacy and safety of reduced dose of Dabigatran, Rivaroxaban and Apixaban in patients with atrial fibrillation for stroke prevention

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Target trial

Most Recent Events

  • 30 Mar 2020 Results evaluating effectiveness of three reduced dose non-vitamin K-antagonists oral anticoagulants (NOACs) to assess treatment effectiveness under different analytic approaches, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
  • 01 Jan 2018 Results published in the Journal of Internal Medicine
  • 29 Sep 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top